The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | Why has CAR-T been more challenging to manufacture for CLL?
In this video, Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, briefly comments on why it has been challenging to manufacture CAR T-cells in chronic lymphocytic leukemia (CLL), highlighting that lisocabtagene maraleucel (liso-cel) has not experienced the same challenges as other agents. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
